Core Insights - Swedish Orphan Biovitrum AB (Sobi) has entered into an acquisition agreement with Arthrosi Therapeutics, Inc. for a total transaction value of up to US$1.5 billion, including an upfront payment of US$950 million and contingent consideration of up to US$550 million, expected to close in the first half of 2026 [1][3]. Company Overview - Arthrosi Therapeutics, Inc. is a late-stage biotechnology company focused on developing pozdeutinurad, a next-generation URAT1 inhibitor aimed at managing gout and tophaceous gout [3][6]. - Sobi is a global biopharma company with approximately 1,900 employees and reported revenue of SEK 26 billion in 2024, dedicated to transforming the lives of individuals with rare diseases [7][8]. Strategic Implications - The acquisition enhances Sobi's gout franchise by adding pozdeutinurad, which is currently in two global Phase 3 clinical studies expected to read out in 2026, potentially becoming a preferred therapy for patients inadequately treated with first-line therapies [3][4]. - The collaboration is anticipated to accelerate growth for Sobi until the mid-2030s and beyond, reflecting a commitment to advancing treatment options for gout patients [4][5]. Financial Impact - Viva Biotech expects the merger to yield an aggregate gain of approximately US$40 million, contingent on regulatory and performance milestones [2].
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.